ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma

Patients with the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) historically showed inferior survival with standard rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Phase II studies demonstrated that adding the immunomodulatory agent...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Principais autores: Nowakowski, Grzegorz S., Chiappella, Annalisa, Gascoyne, Randy D., Scott, David W., Zhang, Qingyuan, Jurczak, Wojciech, Özcan, Muhit, Hong, Xiaonan, Zhu, Jun, Jin, Jie, Belada, David, Bergua, Juan Miguel, Piazza, Francesco, Mócikova, Heidi, Molinari, Anna Lia, Yoon, Dok Hyun, Cavallo, Federica, Tani, Monica, Yamamoto, Kazuhito, Izutsu, Koji, Kato, Koji, Czuczman, Myron, Hersey, Sarah, Kilcoyne, Adrian, Russo, Jacqueline, Hudak, Krista, Zhang, Jingshan, Wade, Steve, Witzig, Thomas E., Vitolo, Umberto
Formato: Artigo
Idioma:Inglês
Publicado em: Wolters Kluwer Health 2021
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8078325/
https://ncbi.nlm.nih.gov/pubmed/33621109
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01366
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados